Different trends in immunosuppression: 10 years' experience with cyclosporine after living related donor renal transplantation.
Bakr
M A
MA
Urology & Nephrology Center, Mansoura, Egypt.
Sally
S
S
Foda
M A
MA
Sobh
M A
MA
el-Sherif
A K
AK
Ghoneim
M A
MA
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D002423:Cause of Death; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005190:Family; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology / Q000473:pathology; D006085:Graft Survival / Q000276:immunology / Q000502:physiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007654:Ketoconazole / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous
D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine; D007654:Ketoconazole